Promacta (eltrombopag) can cause side effects ranging from mild issues like nausea and fatigue to more serious complications, such as cataracts. Promacta has boxed warnings about the potential for ...

Promacta (eltrombopag) is a prescription drug used to treat certain blood disorders, including low platelet level. The drug comes as an oral tablet and an oral liquid suspension. It’s usually taken ...

Promacta can cause mild to serious side effects, ranging from digestive issues to cataracts. This drug has boxed warnings regarding the risk of liver problems in people with chronic hepatitis C and ...

Promacta (eltrombopag) is a brand-name drug that’s prescribed for certain blood disorders. Promacta comes as an oral tablet and liquid suspension that’s typically taken once per day. The dosage can ...

First supportive care treatment approved for patients with thrombocytopenia with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy LONDON, Nov. 19, 2012 ...

GlaxoSmithKline and the FDA notified healthcare professionals of a new safety finding in patients with thrombocytopenia due to chronic liver disease treated with Promacta (eltrombopag tablets). The ...

Promacta ® (eltrombopag) significantly increased and sustained platelet counts in two studies, including the largest Phase III clinical trial in this patient population Characterized by a low platelet ...

The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called ...

(HealthDay)—U.S. Food and Drug Administration approval of the drug Promacta (eltrombopag) has been expanded to include children one year and older with a rare blood disorder called chronic immune ...

Recently, the FDA granted a breakthrough therapy designation to eltrombopag (Promacta, Novartis) for combination use with standard immunosuppressive therapy as a first-line treatment for patients with ...

Updates related to pipeline and label expansion efforts are eagerly awaited by investors in the biotech/pharma space as these play a crucial role in their investment decisions. These updates provide ...